Steroid-enhancing selective casein kinase inhibitors: first in class novel inhaled anti-asthma agents

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1137171

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Chronic lung diseases reduce quality and duration of life of 0.5 billion globally (1 in 4 Australians). Current drugs fail to adequately reduce the decline in lung function. This development is based on the discovery of an enzyme pathway contributing to poor lung function. The project will identify the best doses of the drug and the best combinations with existing drugs to reduce the lung scarring and inflammation. These new findings support efforts to secure investment for clinical testing.

Funded Activity Details

Start Date: 01-01-2018

End Date: 01-01-2019

Funding Scheme: Development Grants

Funding Amount: $538,064.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Pharmacology and Pharmaceutical Sciences not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

asthma exacerbation | asthma therapy | drug action | drug development | respiratory diseases

Related Links